

Financial Results for the First Quarter Ended 30 June 2018 ("1QFY19")



This presentation is focused on comparing actual results from the period from 1 April 2018 to 30 June 2018 ("1QFY19"). Other than the comparative figures presented, no other comparative figures will be presented as the acquisition of the Portfolio of RHT as well as listing on the Singapore Stock Exchange was completed on 19 October 2012.

This presentation may contain forward-looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other developments or companies, shifts in expected levels of income and occupancy rate, changes in operating expenses (including employee wages, benefits and training), governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Investors are cautioned not to place undue reliance on these forward-looking statements. For further information, please also refer to RHT's financial results announcement which is released in conjunction with this set of presentation.

The Indian Rupee and Singapore Dollar are defined herein as "INR" and "S\$" respectively. Any discrepancy between individual amounts and total shown in this presentation is due to rounding.

Unitholders should also note that discussions are currently on-going in relation to the proposed disposal of the entire asset portfolio of RHT to Fortis Healthcare Limited (the "Proposed Disposal"). Unitholders and potential investors are advised to exercise caution in trading the units of RHT as there is no certainty or assurance today that the definitive agreements in relation to the Proposed Disposal will be entered into, the terms and conditions of the Proposed Disposal will not differ from those set out in the Term Sheet, or the Proposed Disposal will be undertaken at all. Unitholders may refer to the various announcements released via SGXNET for more information on the Proposed Disposal.



Portfolio



RHT–18 Quality Assets Spread Across India

RHT:


- Investment mandate to invest in medical and healthcare assets and services in Asia, Australasia and other emerging markets
- A healthcare-related business trust listed on the SGX (current market cap of \$\$627.5m⁽¹⁾)
- Partnership with Fortis Healthcare Limited, the leading healthcare delivery services provider in India

RHT Portfolio Summary:

- Portfolio valued at S\$1,086.4m⁽²⁾⁽³⁾
- 12 RHT Clinical Establishments
- 4 Greenfield Clinical Establishments
- 2 Operating Hospitals managed and operated by RHT

Premier Locations Across India:

- Approximately 3.6 million sq ft of built-up area across 10 states
- Sizeable population catchment
- Located near to major transportation nodes
 - : 100% Owned RHT Clinical Establishment : Greenfield Clinical Establishments : Operating Hospitals : 49% Owned Clinical Establishment
 - commencing 12 October 2016



No. of beds and installed capacities as of 30 June 2018. Potential bed capacity assumes all planned phases of development and construction are completed.

(a) The development of the Mohali land is intended to be carried out in phases and will not result in an immediate addition in capacity of 480 beds upon completion of the initial phase of development.



As at 30 June 2018. Source: SGX.

Notes


(2) Based on S\$1 = INR 49.68 as at 31 March 2018. The appraised value of each of the portfolio's assets by the independent valuers is as at 31 March 2018.

(3) The portfolio value has taken into account the disposal of 51.0% economic interest in FHTL.

Portfolio Providing Upside Exposure

Fee structure offers RHT an ideal combination of cash-flows with opportunity to participate in operational growth of its healthcare assets


٠




Portfolio Valuation Breakdown (FY-18)⁽¹⁾

Note: FHTL owns 49% of the Gurgaon and Shalimar Bagh Clinical Establishments with the remaining 51% owned by FHML






Service Fee Component⁽⁴⁾



Note: Decline in Base Service Fee in FY-19 (annualised) is due to the depreciation of INR against SGD



Note: The figures are presented in the manner with 100% interest in FHTL and includes accounting straight lining

Notes

- Weighted by portfolio valuation. Assets are independently valued by the Independent Valuers in INR terms as at 31 March 2018. (1)
- Financials converted at S\$1 = INR47.41 for FY-15. S\$1 = INR 47.36 for FY-16. S\$1 = INR 48.39 for FY-17. S\$1 = INR 47.72 for FY-18 and S\$1 = INR 50.27 for 1QFY-19. (2)
- Base Service Fee excludes straight lining and includes Technological Renewal Fee and are on a full year basis. (3)
- (4)The figures have taken into account the disposal of 51.0% economic interest in FHTL.


HEALTH

TRUST


Operational Review



Operational Review



Growth from Capacity Expansion ⁽¹⁾⁽²⁾



Notes: (1)

- (2) (3)
- Figures are updated annually. Bed figures at IPO exclude Gurgaon Clinical Establishment as it was under development at the time of Listing. Bed figures for FY-19(P) include bed capacity from ongoing projects currently under development. Installed capacity refers to the maximum number of beds that can be operated at each hospital without further expansion. Potential capacity refers to the maximum number of beds that can be operated at each hospital (4) when all stages of development are completed.



7

HEALTH TRUST

Operational Review

RHT's assets are spread across India with increasing income generated

Portfolio Characteristics			
	ARPOB (INR m)	Occupancy rate	
1Q FY15	12.31	74%	
2Q FY15	12.66	74%	
3Q FY15	13.23	72%	
4Q FY15	12.91	75%	
1Q FY16	13.47	72%	
2Q FY16	12.94	80%	
3Q FY16	13.28	75%	
4Q FY16	13.93	73%	
1Q FY17	14.23	76%	
2Q FY17	14.16	84%	
3Q FY17 ⁽¹⁾	14.17	75%	
4Q FY17 ⁽¹⁾	14.36	71%	
1Q FY18 ⁽¹⁾	15.37	72%	
2Q FY18 ⁽¹⁾	14.17	77%	
3Q FY18 ⁽¹⁾	14.69	71%	
4Q FY18 ⁽¹⁾	15.19	64%	
1Q FY19 ⁽¹⁾	15.28	62%	


Notes:

All figures based on information released by Fortis Healthcare Limited for their Top 10 performing hospitals.


⁽²⁾ Numbers are presented in the manner with 100.0% economic interest in FHTL.

⁽¹⁾ Source: Fortis presentation slides for FY18. Figures are updated annually.

Occupancy in RHT Clinical Establishments⁽²⁾



ARPOB Growth in RHT Clinical Establishments⁽²⁾ (INR m)



Capacity Enhancements



Capacity Enhancements

Hospitals	Current Operational Bed Capacity	Current Installed Bed Capacity	Potential Additional Bed Capacity (ex. Greenfield Clinical Establishments)
Amritsar	158	166	102
Anandpur, Kolkata	200	373	
BG Road, Bengaluru	258	258	200
Gurgaon	290	450	550
Faridabad	210	210	
Jaipur	271	320	
Kalyan, Mumbai	62	62	
Malar, Chennai	151	178	
Mohali	348	355	480 (Mohali land)
Mulund, Mumbai	303	567	
Nagarbhavi, Bengaluru	45	62	45
Noida	191	200	27
Rajajinagar, Bengaluru	48	52	
Shalimar Bagh, New Delhi	229	350	
Total	2,764	3,603	







	Ludhiana Greenfield Clinical Establishment	BG Road Brownfield Clinical Establishment
Estimated Time of Completion	On hold ⁽¹⁾	Oncology – Completed
Estimated Time of Completion		Operating Theatre – On hold ⁽¹⁾
No. of Beds Planned	70	200
Specialties	Mother & Child Programmes	Oncology, Operating Theatre
Civil Cost	INR 880 m (S\$18.0 m)	INR 1,700.8 m (S\$34.0 m)

	Expansion of Mohali Clinical Establishment	
Potential Bed Capacity	480	
Specialties	-	
Cost	Land – INR 730.0 m (S\$14.6m)	
Cost	Building – INR 2,822 m (S\$56.4 m)	



Capacity Enhancements

	Jaipur Clinical Establishment	Mulund Clinical Establishment	Nagarbhavi Clinical Establishment
Estimated Time of Completion	Completed and operations commenced	Completed and operations commenced	On hold ⁽¹⁾
No. of Additional Beds Planned	59	39	45
Purpose	Mother & Child and Orthopedics programme	Mother and Child programme	Addition of 2 operating theatres and a cath lab
Civil Cost	INR 162.9 m (S\$3.3 m)	INR 129.6 m (S\$2.6 m)	INR 198.2 m (S\$4.0 m)
	Amritsar Clinical Establishment	Noida Clinical Establishment	Shalimar Bagh Clinical Establishment
Estimated Time of Completion	On hold ⁽¹⁾	On hold ⁽¹⁾	Completed and operations commenced
No. of Additional Beds Planned	102	27	-
Purpose	Addition of Oncology Block	Addition of state-of-art unit and Gastroenterology	Addition of Oncology programme
Civil Cost	INR 422.6 m (S\$8.5 m)	INR 141.5 m (S\$2.8 m)	INR 196.9 m (S\$3.9 m)




Financial Highlights




Financial Highlights


Yield, gearing & P/B⁽¹⁾




Net Asset Value (S\$ m)



Yield over the financial years (2)(3)



Distributable Income (S\$ m) – Y-o-Y comparison



(a) Drop in yield due to the Disposal of a 51.0% economic interest in Fortis Hospotel Limited ("FHTL" and the "Disposal")


Notes:

- (1) RHT's current yield, gearing and P/B are based on the unit price of \$\$0.775 as at 30 June 2018. Gearing ratio takes into consideration ongoing and future asset enhancement initiatives (BG Road, Ludhiana, Mulund, Nagarbhavi, Amritsar and Noida Clinical Establishments and expansion of Mohali Clinical Establishments).
- (2) Figures for yield of annualised FY-19 is based on a total number of Common Units of 809,643,944 as at 30 June 2018. Figures for yield for FY-15, FY-16, FY-17 and FY-18 are based on the unit price of the respective financial year end for illustrative purposes.
- (3) Commencing FY-17, RHTTM is distributing 95% of its Distributable Income. 100% of Distributable Income was paid out before FY-17.



Period	Distributable Income attributable for Distribution (cents)
4QFY18	1.06 cents per unit ⁽¹⁾
1QFY19	1.00 cents per unit ⁽²⁾

DPU (Singapore cents) Y-o-Y comparison ⁽³⁾



Notes:

(1) Distributions are paid on a semi-annual basis for the six-month periods ending 31 March and 30 September of each year.

(2) Based on total number of Common Units of 809,643,944 currently issued as at 30 June 2018.

(3) DPU represents 95% of Distributable Income. 100% of Distributable Income was paid out before FY17.



S\$'000	1Q FY19	4Q FY18	Variance (%)	1Q FY18	Variance (%)
Average rate ⁽¹⁾	50.27	49.17	2.2	46.59	7.9
Effective forward rate	51.00 ⁽²⁾	51.75 ⁽³⁾	(1.4)	49.35 ⁽³⁾	(3.3)
Total Revenue ⁽⁴⁾	21,995	23,128	(4.9)	24,108	(8.8)
Net Service Fee and Hospital Income	12,599	13,678	(7.9)	13,581	(7.2)
Cash flow from FHTL ⁽⁵⁾	4,163	5,381	(22.6)	4,474	(7.0)
RHT Income available for distribution	4,388	3,710	18.3	5,971	(26.5)
Total Distributable Income	8,551	9,091	(5.9)	10,445	(18.1)
Distribution	8,123	8,636	(5.9)	9,923	(18.1)
Distribution per unit (cents)	1.00	1.06	(5.7)	1.22	(18.0)

Notes:

- (1) Average rate throughout the quarter. This is used to compute the revenue and expenses.
- (2) Based on estimated forward rate. No hedge has been entered into for FY19.
- (3) The Trustee-Manager has hedged 50% of the expected INR cash flow, leaving the remaining unhedged portion of INR cash flow to be realised at spot rate. The Trustee-Manager assumed a forward rate for the unhedged INR cash flow to determine the Distributable Income. Any difference between the actual spot rate and the estimated forward rate will be adjusted in the next distribution. The average forward rate disclosed is the weighted average of the contracted forward rate and the estimated forward rate used to determine the Distributable Income.




(5) RHT's share of cash flow from FHTL, where it owns 49.0% economic interest.



Revenue (S\$'000) (1)(2)(3)

Revenue (INR '000) (1)(2)(3)



FHTL Base Fee Variable Fee Hospital Income Other Income

Notes:


- (1) Exchange rate for translation at S\$1 = INR for FY-15 to FY-18 are 47.41, 47.36, 48.39 and 47.72 respectively. Actual exchange rate for 1QFY-19 was S\$1 = INR 50.27.
- (2) Excludes straight-lining of Base Service Fee. FY-15 figures include a one-off gain on acquiring the Mohali Clinical Establishment.
- (3) FY-17 includes 100.0% of FHTL's revenue up till 12 October 2016 and 49.0% share of FHTL's revenue from 13 October 2016 onwards.

Capital Structure



Capital Structure

Indicator	As at 30 June 2018
Interest service coverage (Adjusted EBITDA/Interest expense)	3.79
Percentage of fixed interest rate debt	50.9%
Percentage of unsecured borrowings	51.7%
Effective weighted average cost of debt	6.8%
Gearing ratio	24.4%



Notes:

- (1) As at 30 June 2018, gross of upfront fees excluding NCD.
- (2) Defined as Net Debt, being total loans and borrowings less cash and cash equivalents.
- (3) Gearing ratio takes into consideration ongoing and future asset enhancement initiatives.

(4) Gearing is calculated as Net Debt divided by sum of Net Assets and Net Debt, excluding NCD liabilities owing to an associate.



For further information please contact:

Tan Suan Hui Head of Compliance and Investor Relations

RHT Health Trust Manager Pte. Ltd 302 Orchard Road #09-03/04 Tong Building Singapore 238862


Email: suanhui.tan@rhealthtrust.com www.rhealthtrust.com



Appendix



Financial Highlights



Notes:

(1) Exchange rate for translation at S\$1 = INR for FY-15 to FY-18 are 47.41, 47.36, 48.39 and 47.72 respectively. Actual exchange rate for 1QFY19 was S\$1= INR 50.27.

(2) Excludes non-recurring items.

(3) Excludes straight-lining, depreciation and amortization.

(4) FY-17 includes 100.0% of FHTL's performance up till 12 October 2016 and 49% share of FHTL's results from 13 October 2016 onwards.

(5) S\$1 = INR for FY-15 to FY-19 are 45.43, 49.17, 46.43, 49.68 and 50.25 respectively.



Review of 1Q FY19 against 1Q FY18 Performance

1Q FY18

S\$'000

Portfolio			
1Q FY18	against	1Q FY19 (q-o-q)	

Total Revenue ⁽¹⁾	24,108
Net Service Fee and Hospital Income ⁽²⁾	13,581

FHTL⁽³⁾

1Q FY18 against 1Q FY19 (q-o-q)	1
Tatal Davianua(1)	
Total Revenue ⁽¹⁾ Net Service Fee and Hospital Income ⁽²⁾	

13,581	12,599	(7.2)
		I
1Q FY18	1Q FY19	Variance
S\$'000	S\$'000	% (8.0)
13,900	12,791	(8.0)

10.613

1Q FY19

S\$'000

21,995

Variance

%

(8.8)

(7.5)

534,444

1Q FY18	1Q FY19	Variance
INR'000	INR'000	%
1,123,072	1,105,566	(1.6)
632,644	633,250	0.1
1Q FY18	1Q FY19	Variance
INR'000	INR'000	%
647,608	642,941	(0.7)

533.414

	1Q FY18	1Q FY19	Variance (%)
Adjusted net service fee margin ⁽⁴⁾	62%	63%	1.0
Distributable Income (S\$'000)	10,445	8,551	(18.1)

11,475

Exchange rate for actual 4QFY18 was S\$1 = INR 49.17, 1QFY19 was S\$1 = INR 50.27.

- (1) Excludes straight-lining.
- (2) Excludes straight-lining, depreciation and amortisation.
- (3) 100% of FHTL's performance has been used for comparison.

(4) Adjusted net service fee margin takes into account the performance of FHTL which was accounted for as an associate.



(0.2)

Review of 1Q FY19 against 4Q FY18 Performance

Portfolio						
4Q FY18 against 1Q FY19 (q-o-q)	4Q FY18	1Q FY19	Variance	4Q FY18	1Q FY19	Variance
	S\$'000	S\$'000	%	INR'000	INR'000	%
Total Revenue ⁽¹⁾	23,128	21,995	(4.9)	1,138,044	1,105,566	(2.9)
Net Service Fee and Hospital Income ⁽²⁾	13,678	12,599	(7.9)	671,969	633,250	(5.8)
<u>FHTL(3)</u>						
4Q FY18 against 1Q FY19 (q-o-q)	4Q FY18	1Q FY19	Variance	4Q FY18	1Q FY19	Variance
	S\$'000	S\$'000	%	INR'000	INR'000	%
Total Revenue ⁽¹⁾	12,952	12,791	(1.2)	637,993	642,941	0.8
Net Service Fee and Hospital Income ⁽²⁾	11,158	10,613	(4.9)	548,992	533,414	(2.8)
			-			-

	4Q FY18	1Q FY19	Variance (%)
Adjusted net service fee margin ⁽⁴⁾	65%	63%	(2.0)
Distributable Income (S\$'000)	9,091	8,551	(5.9)

Exchange rate for actual 4QFY18 was S\$1 = INR 49.17, 1QFY19 was S\$1 = INR 50.27.

(1) Excludes straight-lining.

(2) Excludes straight-lining, depreciation and amortisation.

(3) 100% of FHTL's performance has been used for comparison.

(4) Adjusted net service fee margin takes into account the performance of FHTL which was accounted for as an associate.



Financial Results for 1Q FY19

For the quarter ended 30 June 2018

	1Q FY19	1Q FY18	
	S\$'000	S\$'000	Var (%)
Revenue:			
Service fee	18,738	20,922	(10)
Hospital income	2,569	2,541	1
Other income	930	1,050	(11)
Total revenue	22,237	24,513	(9)
Total service fee and hospital expenses	(12,143)	(13,568)	(11)
Finance Income ⁽¹⁾	3,878	4,147	(6)
Finance Expenses ⁽²⁾	(5,258)	(4,152)	27
Trustee-Manager Fees	(1,345)	(1,351)	0
Other Trust Expenses	(672)	(1,152)	(42)
Foreign exchange loss	(847)	(3,369)	n.m.
Total expenses	(16,387)	(19,445)	(16)
Share of results of an associate	2,281	2,871	(21)
Profit before changes in fair value of financial derivatives	8,131	7,939	2
Fair value (loss)/gain on financial derivatives	(389)	2,870	n.m.
Profit before taxes	7,742	10,809	(28)
Income tax expense	(3,756)	(1,628)	131
Profit for the period attributable to Unitholders of the Trust	3,986	9,181	(57)

(1) The finance income includes CCD interest income (refer to Note 9 in Announcement).

(2) The finance expenses includes NCD interest expenses (refer to Note 10 in announcement). n.m – not meaningful.

Exchange rate for translation for actual 1QFY18 was S\$1 = INR 46.59. 1QFY19 was S\$1 = INR 50.27.



Financial Results for 1Q FY19

For the quarter ended 30 June 2018

Reconciliation to Unitholders Distributable Income

	1Q FY19 S\$'000	1Q FY18 S\$'000
Profit for the period attributable to Unitholders of the Trust	3,986	9,181
Distribution adjustments:		
Impact of non-cash straight-lining	(242)	(405)
Technology renewal fee	(155)	(167)
Depreciation and amortisation	2,747	3,041
Trustee-Manager fees payable in units	672	675
Tax adjustment	1,209	(1,020)
Foreign exchange differences	1,033	(344)
Compulsorily Convertible Debentures ("CCD") interest income	(3,702)	(3,994)
Non-Convertible Debentures ("NCD") interest expense	1,836	1,792
Non-cash adjustments of an associate	1,882	1,603
Others	(715)	83
Total Distributable Income attributable to Unitholders of the Trust	8,551	10,445



Financial Results and Cash Flow of FHTL for 1Q FY19

For the quarter ended 30 June 2018

	1Q FY19 - Associate	1Q FY18 - Associate
	S\$'000	S\$'000
Revenue:		
Total revenue	13,472	14,799
Total expenses	(6,604)	(7,771)
Profit before tax	6,868	7,028
Income tax expense	(2,212)	(1,168)
Profit for the year	4,656	5,860
Share of 49.0% of profit for the period	2,281	2,871
Non-cash adjustments		
Impact of non-cash straight-lining	(681)	(899)
Technology renewal fee	(9)	(10)
Depreciation and amortisation	1,471	1,654
Tax Adjustment	12	(1,085)
Capital expenditure	-	(56)
Interest income and expense with related parties	3,048	3,667
FHTL's non-cash adjustments	3,841	3,271
Share of 49.0% of non-cash adjustment	1,882	1,603
-		
Net cash flow from FHTL (excluding common expenses)	8,497	9,131
Share of 49.0% of net cash flow from FHTL	4,163	4,474




Balance Sheet

(S\$ '000)	30 June 18	31 March 18
Intangibles	85,391	86,781
PPE	533,061	539,011
Other long term assets	55,457	56,921
Investment in associate	365,838	363,557
Long term liabilities	(304,409)	(254,322)
Net current liabilities	(82,374)	(129,411)
Total net assets attributable to Unitholders	652,964	662,537



Trustee-Manager Fee Structure

Performance based management fees designed to align Management's interests with Unitholders




Development fee	Asset management fee
 2.0% of total development project costs Payable in the form of cash and/ or units 	 1.0% of gross revenue Paid quarterly in arrears No asset management fee paid for assets operated by Sponsor



Unit Price Performance Against Peers

For the quarter 1 April 2018 to 30 June 2018



			Price				Volume		
Name	Code	Cur	Open	High	Low	Close	Change %	Total Volume	Daily Average Volume
Ascendas India Trust	CY6U.SGX	SGD	1.01	1.08	1.00	1.01	0.00	48,687,300	772,814
Parkway Life REIT	C2PU.SGX	SGD	2.80	2.81	2.58	2.72	(2.86)	40,239,400	638,721
First Real Estate Investment Trust	AW9U.SGX	SGD	1.38	1.39	1.32	1.33	(3.62)	47,219,700	749,519
RHT Health Trust	RF1U.SGX	SGD	0.81	0.81	0.745	0.775	(4.32)	56,164,400	891,498
FTSE ST All-Share Index - Real Estate Investment Trusts REIT	FSTAS8670	SGD	818.49	829.10	774.83	786.10	(3.96)		



Jaipur Clinical Establishment

- Completed its 50th successful kidney transplant.
- Achieved zero 30 days Mortality, zero Graft Nephrectomy, zero Re-Exploration and zero Surgical Wound Infection.
- Achieved a 100% take home kidney rate.

Malar Clinical Establishment

- Completed more than 125 successful heart transplants.
- Successfully completed 342 kidney transplants till date.

Mulund Clinical Establishment

- Conducted its 35th successful heart transplant.
- Conducted first ever heart and lung transplant on a patient suffering from Congenital Ventricular Septal Defect.

BG Road Clinical Establishment

• Performed 101 Neurosurgeries in October 2016.

Noida Clinical Establishment

Achieved 500th Liver Transplant milestone.



Awards & Accolades

RHT featured as one of "Asia's Top 50 Healthcare Providers" by Frost and Sullivan



Jaipur Clinical Establishment

- Won top honours at the Quality Council of India-D.L. Shah Awards for the fifth time consecutively in 2017.
- Won the Quality Council of India ("QCI") D.L. Shah Award for the fourth time in a row under Lean Six Sigma project titled "Dock to Stock Cycle Reduction Time in Critical Care Kaizen".



Anandpur Clinical Establishment

- 2nd Best Hospital in Multi-specialty category in Kolkata in a survey conducted by AC Nielson for The Week Magazine.
- Received the prestigious National Energy Conservation Award from the President of India.



BG Road Clinical Establishment

- Awarded as the "Best Medical Tourism Hospital" at the Karnataka Tourism Awards 2016.
- Awarded "Best Patient Safety Initiative", "Best CSR Practices in Healthcare" and "Best Use of Social Medial and Digital Marketing" at Times Television Network National Marketing Excellence Awards 2017.



Awards & Accolades



Mulund Clinical Establishment

- Awarded the "Best Hospital Unit in Cardiac Care" and the "Best Medical Tourism Facility" at the CIMS Healthcare Excellence Awards 2016.
- Project 'One Fortis: Training in Action' won at the Asian Hospital Management Awards 2017
- Awarded top honors at the CII 18th National Awards for Excellence in Energy Management in building category.



Gurgaon Clinical Establishment

- 2nd globally on '30 Most Technologically Advanced Hospitals in the World' by 'topmastersinhealthcare.com'.
- "Won two awards under "Process Innovation" and "Safety" categories of Frost and Sullivan 's Project Evaluation & Recognition Programme 2015.



Malar Clinical Establishment

- Won the top honors at the CII 18th National Awards for Excellence in Energy Management in the Building Category.





Faridabad Clinical Establishment

- Recognized as the "Best Heart Hospital" at the double helical State Health Awards 2017.



Noida Clinical Establishment

- Won 'Comprehensive Neurosciences Service Provider of the Year' award at Frost and Sullivan's 7th Annual India Healthcare Excellence Awards 2015.
- National Energy Conservation Award.



Mohali Clinical Establishment

- Recognized as Best Hospital in Paediatric Cardiac Sciences at the 3rd Advantage Healthcare India 2017.
- Won top honors at the CII 18th National Awards for Excellence in Energy Management in building category

